PIPERACILLIN SODIUM; TAZOBACTAM SODIUM: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eugia Pharma	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	217409	ANDA	Eugia US LLC	55150-473-01	1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (55150-473-01) / 152 mL in 1 VIAL, PHARMACY BULK PACKAGE	2023-10-12
Eugia Pharma	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	217409	ANDA	Eugia US LLC	55150-474-01	1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (55150-474-01) / 51 mL in 1 VIAL, PHARMACY BULK PACKAGE	2023-10-12
Eugia Pharma Speclts	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065498	ANDA	Eugia US LLC	55150-119-30	10 VIAL in 1 BOX (55150-119-30) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2012-01-23
Eugia Pharma Speclts	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065498	ANDA	Eugia US LLC	55150-119-09	10 VIAL in 1 BOX (55150-119-09) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2012-01-23
Eugia Pharma Speclts	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065498	ANDA	Eugia US LLC	55150-120-30	10 VIAL in 1 BOX (55150-120-30) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2012-01-23
Eugia Pharma Speclts	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065498	ANDA	Eugia US LLC	55150-120-09	10 VIAL in 1 BOX (55150-120-09) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2012-01-23
Eugia Pharma Speclts	PIPERACILLIN AND TAZOBACTAM	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	065498	ANDA	Eugia US LLC	55150-121-50	10 VIAL in 1 BOX (55150-121-50) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2012-01-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the global supply chain for piperacillin sodium and tazobactam sodium, critical active pharmaceutical ingredients (APIs) used in combination antibiotic therapies. It identifies key manufacturers, production capacities, regulatory standing, and market trends impacting availability and pricing.

Who are the Primary Manufacturers of Piperacillin Sodium?

Manufacturing of piperacillin sodium is concentrated among a limited number of global suppliers. These manufacturers operate with varying scales of production and adhere to distinct regulatory frameworks.

Core Suppliers:
- Sandoz (Novartis): Operates manufacturing facilities in multiple geographies, including India and Europe. Holds a significant share of the global market.
- Teva Pharmaceutical Industries: A major player with API production sites in Israel and North America.
- Fresenius Kabi: Focuses on injectable formulations, sourcing APIs from integrated production sites and third-party manufacturers.
- Hikma Pharmaceuticals: Has a strong presence in North America and Europe, with API sourcing from its own facilities and contract manufacturers in Asia.
- Amneal Pharmaceuticals: Primarily serves the US market, with API manufacturing in India and the United States.
Emerging and Regional Manufacturers: Several companies, particularly in China and India, have increased their production capacity in recent years. These include:
- Nanjing King-Sun New Material Co., Ltd. (China): Known for penicillin-class antibiotics.
- Suzhou First Pharmaceutical Co., Ltd. (China): A significant producer of antibiotic APIs.
- Laurus Labs (India): While more known for other API classes, it has diversified into semi-synthetic penicillins.
- Aurobindo Pharma (India): A large API producer with a broad portfolio, including beta-lactam antibiotics.

These manufacturers generally operate under Good Manufacturing Practices (GMP) and are subject to inspection by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). The production process involves fermentation of Penicillium chrysogenum for the core penicillin structure, followed by semi-synthetic modification to yield piperacillin.

What is the Production Capacity for Tazobactam Sodium?

Tazobactam sodium production is more consolidated than piperacillin sodium. Its complex synthetic pathway requires specialized chemical synthesis capabilities.

Leading Global Producers:
- DSM (Netherlands): A major supplier of pharmaceutical ingredients, including tazobactam. Operates integrated manufacturing facilities.
- Merck & Co. (USA): While primarily a finished drug producer, it has historically had internal API manufacturing capabilities or significant long-term supply agreements for key components.
- Centrient Pharmaceuticals (formerly an Actavis/Pfizer division, now independent): Significant presence in antibiotic API manufacturing, including beta-lactamase inhibitors like tazobactam. Operates large-scale facilities in India and Spain.
- Sino-American Pharmaceutical (China): Has emerged as a key supplier of tazobactam sodium, leveraging cost-effective synthesis routes.
- Granules India Ltd. (India): A prominent API manufacturer with growing capabilities in sterile APIs and advanced intermediates.

The synthesis of tazobactam sodium is a multi-step process that requires precise control over chemical reactions and purification. Key intermediates are often sourced globally, adding complexity to the supply chain. Production capacity is measured in metric tons per year, with aggregate global capacity estimated to be between 200-300 metric tons annually, though precise figures are proprietary.

What are the Regulatory Requirements for these APIs?

Both piperacillin sodium and tazobactam sodium require stringent adherence to pharmaceutical regulations to ensure quality, safety, and efficacy.

Key Regulatory Bodies and Standards:
- U.S. Food and Drug Administration (FDA): Manufacturers must comply with 21 CFR Part 210 and 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals) and relevant API guidelines. Site inspections are mandatory for products intended for the US market. Drug Master Files (DMFs) are typically filed for APIs.
- European Medicines Agency (EMA): Adherence to EudraLex Volume 4, Part II (Basic Requirements for Active Substances used as Starting Materials) is required. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often sought.
- World Health Organization (WHO): For inclusion in the WHO Model List of Essential Medicines and prequalification programs, APIs must meet WHO GMP standards and undergo stringent quality assessment.
- Pharmacopoeial Standards: Compliance with USP (United States Pharmacopeia), EP (European Pharmacopoeia), JP (Japanese Pharmacopoeia), and IP (Indian Pharmacopoeia) monographs is essential. These standards define purity, impurity profiles, and analytical methods.
Recent Regulatory Actions:
- FDA Warning Letters and Import Alerts: Have been issued to several API manufacturers in Asia for cGMP violations, impacting product availability and requiring remediation efforts.
- EMA Inspections: Continuous scrutiny of manufacturing sites, particularly for antibiotic APIs, due to concerns over antibiotic resistance and supply chain integrity.

Which Markets are the Largest Consumers of Piperacillin/Tazobactam?

The primary markets for piperacillin sodium and tazobactam sodium are regions with high demand for broad-spectrum injectable antibiotics, driven by hospital settings and the prevalence of serious bacterial infections.

Top Consuming Regions (by volume):
- North America (USA, Canada): High utilization in hospitals due to established treatment protocols for nosocomial infections.
- Europe (Germany, UK, France, Italy): Significant demand driven by healthcare systems with high rates of antibiotic use in hospitals.
- Asia-Pacific (China, India, Japan): Growing demand fueled by expanding healthcare infrastructure and increasing incidence of infectious diseases. India is also a major producer and exporter.
- Latin America (Brazil, Mexico): Increasing demand as healthcare access improves.
Market Drivers:
- Hospital-Acquired Infections (HAIs): Piperacillin/tazobactam is a frontline treatment for common HAIs caused by Gram-negative and Gram-positive bacteria, including Pseudomonas aeruginosa.
- Sepsis and Severe Infections: Its broad spectrum of activity makes it crucial for empirical treatment of severe infections.
- Antibiotic Resistance Patterns: The drug's efficacy against certain resistant strains maintains its relevance.
- Availability of Generic Formulations: The expiration of primary patents has led to a competitive generic market, increasing accessibility.

What are the Key Supply Chain Risks and Mitigation Strategies?

The supply chain for piperacillin sodium and tazobactam sodium faces several inherent risks, demanding proactive management by pharmaceutical companies.

Identified Risks:
- Geopolitical Instability: Concentration of API manufacturing in specific regions (e.g., China, India) makes the supply chain vulnerable to trade disputes, natural disasters, or political unrest.
- Regulatory Non-Compliance: Findings of GMP violations by regulatory bodies can lead to import bans or product recalls, disrupting supply. For example, the FDA has previously placed import alerts on APIs from specific Chinese manufacturers.
- Quality Control Issues: Batch-to-batch consistency and impurity profiling are critical. A single quality failure can lead to significant product shortages.
- Raw Material Scarcity: Production of key intermediates can be subject to shortages or price volatility.
- Logistical Disruptions: Global shipping delays, port congestion, and transportation costs can impact timely delivery of APIs.
- Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs can lead to temporary plant closures or increased production costs.
Mitigation Strategies:
- Dual Sourcing: Qualifying multiple suppliers for both piperacillin sodium and tazobactam sodium across different geographic regions to reduce reliance on any single entity.
- Inventory Management: Maintaining strategic safety stocks of APIs and finished drug products to buffer against short-term disruptions.
- Supplier Audits and Qualification: Rigorous and regular audits of manufacturing sites to ensure ongoing compliance with GMP and quality standards. This includes not only tier-1 but also tier-2 suppliers for critical raw materials.
- Long-Term Supply Agreements: Securing predictable supply and pricing through contractual arrangements with key manufacturers.
- Regulatory Intelligence: Proactive monitoring of regulatory changes and enforcement actions in key manufacturing countries.
- Supply Chain Visibility Tools: Implementing technology to track shipments, monitor supplier performance, and identify potential bottlenecks in real-time.
- Investment in Domestic/Regional Manufacturing: Companies are exploring onshoring or nearshoring options for critical APIs to reduce geopolitical risk, though cost remains a significant factor.

What are the Market Trends and Future Outlook?

The market for piperacillin sodium and tazobactam sodium is influenced by global health trends, antibiotic stewardship initiatives, and evolving regulatory landscapes.

Key Market Trends:
- Increasing Demand for Injectable Antibiotics: Driven by aging populations and the rising incidence of complex infections in hospital settings.
- Focus on Antibiotic Stewardship: Efforts to curb antimicrobial resistance (AMR) may moderate growth in some regions but also highlight the importance of effective, broad-spectrum agents like piperacillin/tazobactam for critical care.
- Consolidation of Manufacturers: The API market is experiencing consolidation, with larger players acquiring smaller ones to gain market share and vertical integration.
- Technological Advancements in Synthesis: Research into more efficient and environmentally friendly synthesis routes for tazobactam sodium.
- Impact of Global Health Crises: Events like the COVID-19 pandemic have exposed supply chain vulnerabilities, leading to increased scrutiny and a push for diversification.
- Emergence of New Antibiotic Classes: While piperacillin/tazobactam remains a cornerstone, the development of novel antibiotics targeting multi-drug resistant organisms could eventually impact its market share in specific indications.
Future Outlook:
- The market is expected to remain robust, driven by its established efficacy and role in hospital-based care.
- Pricing will likely continue to be influenced by competitive generic pressures and raw material costs.
- Regulatory oversight will intensify, favoring manufacturers with strong compliance records and robust quality management systems.
- Supply chain resilience will be a paramount concern, leading to increased investment in diversification and risk mitigation strategies.
- The geographic distribution of manufacturing is unlikely to shift dramatically in the short term due to high capital investment and specialized expertise required, but gradual diversification efforts will continue.

Key Takeaways

Piperacillin sodium manufacturing is broadly distributed, with significant capacity in India and China alongside established Western players.
Tazobactam sodium production is more consolidated, with fewer primary global suppliers, increasing its supply chain criticality.
Regulatory compliance is a primary driver of market access and supplier viability, with ongoing scrutiny from FDA and EMA.
North America and Europe are the largest consuming markets, but Asia-Pacific shows significant growth.
Supply chain risks include geopolitical factors, regulatory non-compliance, and quality control issues, necessitating dual sourcing and robust inventory management.
The market outlook remains positive due to its essential role in hospital settings, though it will be shaped by AMR initiatives and evolving regulatory demands.

Frequently Asked Questions

What is the primary regulatory filing required for piperacillin sodium and tazobactam sodium APIs to be sold in the United States? Manufacturers typically file Drug Master Files (DMFs) with the U.S. Food and Drug Administration (FDA) for APIs. These confidential documents contain detailed information about the manufacturing process, facility, and quality controls, which are reviewed by the FDA when a finished drug product application referencing the DMF is submitted.
How has the consolidation of pharmaceutical companies affected the supply of these APIs? Consolidation among API manufacturers can lead to a more concentrated supply base, potentially increasing reliance on fewer entities. However, it can also lead to greater investment in quality control and supply chain optimization by larger, more established companies. For smaller, specialized API producers, acquisition by larger entities can provide greater financial backing and market access.
What are the typical lead times for sourcing piperacillin sodium and tazobactam sodium from manufacturers? Lead times can vary significantly based on order volume, current manufacturer backlogs, and shipping logistics. For standard orders, lead times can range from 8 to 16 weeks. However, for large volumes or in periods of high demand or supply disruption, lead times can extend to 6 months or more.
Are there any significant environmental concerns associated with the production of these APIs? The chemical synthesis of tazobactam sodium, in particular, can involve the use of solvents and reagents that require careful waste management and disposal. Manufacturing facilities, especially in regions with less stringent enforcement, may face scrutiny regarding effluent treatment and emissions. Companies are increasingly investing in greener chemistry and advanced waste treatment technologies to comply with evolving environmental regulations.
What impact do price fluctuations in raw materials, such as penicillin G for piperacillin, have on the final API cost? The cost of key raw materials, particularly for the fermentation-derived component of piperacillin, directly influences the API's production cost. Volatility in agricultural commodities or upstream chemical intermediates can lead to price increases for the final piperacillin sodium API. Similarly, the complexity of tazobactam synthesis means its cost is sensitive to the price and availability of its specialized chemical precursors. These fluctuations are often passed on to finished drug manufacturers.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA Website] (Specific URL not provided as it's a regulatory code)

[2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA Website] (Specific URL not provided as it's a regulatory code)

[3] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good Manufacturing Practice. Retrieved from [EMA Website] (Specific URL not provided as it's regulatory guidance)

[4] World Health Organization. (2010). WHO good manufacturing practices for pharmaceutical products: main principles. Geneva: World Health Organization.

[5] United States Pharmacopeia. (n.d.). USP General Chapters. Retrieved from [USP Website] (Specific URL not provided as it's a compendium)

[6] European Pharmacopoeia. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from [EDQM Website] (Specific URL not provided as it's a compendium)

Suppliers and packagers for generic pharmaceutical drug: PIPERACILLIN SODIUM; TAZOBACTAM SODIUM